Skip to main content
Premium Trial:

Request an Annual Quote

Angle Raises Additional £2.8M in Share Placement

NEW YORK (GenomeWeb) – Liquid biopsy developer Angle announced today that it has raised £2.8 million ($3.7 million) through a subscription for approximately 7.5 million new ordinary shares at 37.5 pence each.

The deal represents a follow-on to the placement earlier this month of about 34.8 million new ordinary shares at 35 pence per share, which grossed £12.2 million. The company said that the further subscription was entered into in order to allow participation by an investor who was unable to complete the necessary paperwork in time for the original fundraising.

Angle Founder and CEO Andrew Newland said in a statement that the funding will help the company pursue commercial partnerships for its Parsortix circulating tumor cell system and close its previously announced £3.7 million acquisition of University of Toronto microarray spinout Axela.